Timely reports on clinical research, legislative updates and product launches, from the editors of Review of Optometry and RCCL. Stories post each weekday morning.
While both surgical and medical treatments are viable for newly diagnosed advanced cases, the financial burden with the former option doesn’t necessarily compensate for its greater effect.
Reported receipt of any non-research support from pharmaceutical manufacturers, regardless of amount, was associated with an almost doubled probability of a prostaglandin drug Rx.
Findings include increased fluorescein staining, decreased tear film breakup time, decreased corneal subbasal nerve plexus density and reduced corneal sensitivity.
The legislation would permit ODs to perform three laser surgeries, remove lid lesions, give injections and do corneal crosslinking. Backers say rigorous training requirements might mollify detractors.
A new study suggests that step therapy beginning with off-label bevicizumab, which significantly reduces cost, likely has no deleterious impact on treatment efficacy.